氟伏沙明与氟西汀治疗抑郁症急性期患者的效果和安全性研究
Efficacy and safety of fluvoxamine versus fluoxetine in treatment of patients during acute phase of depression
李浩 1靳自斌 1林雪飞2
作者信息
- 1. 徐州医科大学附属徐州东方医院心理科,徐州 221000
- 2. 徐州市民政精神病医院精神科,徐州 220005
- 折叠
摘要
目的 探究氟伏沙明与氟西汀对抑郁症急性期患者的疗效.方法 挑选2021年12月至2023年9月徐州医科大学附属徐州东方医院心理科收治的抑郁症急性期患者124例为研究对象,采用随机数字表法均分为两组.对照组62例给予氟西汀20 mg·d-1,1次·d-1,观察组62例给予氟伏沙明50 mg·d-1,1次·d-1,疗程共8周.对比两组患者的临床疗效、超敏C反应蛋白(hs-CRP)水平变化及不良反应发生情况.结果 治疗8周后,两组汉密尔顿抑郁量表(HAMD-17)评分较治疗前均降低;治疗后观察组HAMD-17评分为(8.33±1.29)分,低于对照组的(11.35±1.54)分,均差异有统计学意义(均P<0.05).观察组总有效率为90.32%,高于对照组74.19%,差异有统计学意义(P<0.05).hs-CRP水平相较于治疗前,治疗后两组患者全部出现下降情况;且观察组为(3.82±1.20)mg·L-1,较对照组的(4.32±1.47)mg·L-1低(均P<0.05).观察组不良反应发生率为9.68%,低于对照组的17.74%,但差异无统计学意义(χ2=1.704,P>0.05).结论 氟伏沙明对抑郁症急性期患者的疗效优于氟西汀,可以降低hs-CRP水平,改善炎症反应和免疫功能,且安全性高.
Abstract
Objective To explore the clinical efficacy of fluvoxamine and fluoxetine in treatment of patients during acute phase of depression.Methods One hundred and twenty-four patients with acute phase of depression attending Psychology Department of Xuzhou Oriental People's Hospital from December 2021 to September 2023 were included,and grouped using random number ta-ble method,with 62 in each.The patients in the control group received fluoxetine(20 mg·d-1,once a day),while those in the observa-tion one fluvoxamine(50 mg·d-1,once a day).Treatment in both groups lasted for 8 weeks.Then the clinical efficacy,high-sensitivity C-reactive protein(hs-CRP)levels and the occurrence of adverse reactions were compared between the two groups.Results After treatment for 8 weeks,the HAMD-17 scores of both groups were lower than those before treatment,and the HAMD-17 score of the observation group(8.33±1.29)was lower than that of the control(11.35±1.54)after treatment,and the difference was statistically significant(P<0.05).Observation group reported higher clinical efficacy rate as compared to the control(90.32%vs 74.19%,P<0.05).A reduction was found in hs-CRP in all patients after treatment,and study group showed a lower hs-CRP level than the control((3.82±1.20)mg·L-1 vs(4.32±1.47)mg·L-1,both P<0.05).The incidence of adverse reactions in the observation group(9.68%)was lower than that in the control(17.74%),but the difference was not statistically significant when comparing the two groups(χ2=1.704,P>0.05).Conclusion Fluvoxamine is superior to fluoxetine in the treatment of patients during the acute phase of depression,which can decrease hs-CRP levels,attenuate inflammatory response,improve immune function,promote the recovery of patients and has a good safety profile.
关键词
氟伏沙明/氟西汀/抑郁症/临床疗效/超敏C反应蛋白Key words
Fluvoxamine/Fluoxetine/Depression/Clinical efficacy/High-sensitivity C-reactive protein引用本文复制引用
出版年
2024
NETL
NSTL
万方数据